ICI for RCC has grown into a routine aspect of the treatment regimen, including monoclonal antibodies directed against the antigens programmed cell death 1 (PD-1) and cytotoxic T lymphocyte antigen 4 (CTLA-4). This evidence concerns the gene PDCD1 and renal cell carcinoma.